Grufity logoGrufity logo

RGEN

186.05USD-2.12(-1.13%)Market Closed

Repligen Corp

Market Summary

USD186.05-2.12Market Closed
-1.13%

RGEN Alerts

RGEN Stock Price

RSI Chart

Valuation

Market Cap

10.1B

Price/Earnings

63.34

Price/Sales

12.97

Price/Cashflow

71.66

MarketCap/EBT

51.85

Price/Sales

Profitability

EBT Margin

25.01%

Return on Equity

8.83%

Return on Assets

6.52%

Fundamentals

Revenue

Revenue (TTM)

801.3M

Revenue Y/Y

12.64%

Revenue Q/Q

-3.32%

Earnings

Earnings (TTM)

166.3M

Earnings Y/Y

20.62%

Earnings Q/Q

-18.96%

Price Action

52 Week Range

137.21274.09
(Low)(High)

Last 7 days

8.4%

Last 30 days

8.5%

Last 90 days

-11.5%

Trailing 12 Months

-30.8%

Financial Health

Current Ratio

2.3

Investor Care

Shares Dilution (1Y)

0.43%

Diluted EPS (TTM)

2.9

Peers (Alternatives to Repligen)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
41.1B
6.7B
15.08% 3.58%
30.93
6.17
8.42% 34.14%
36.7B
4.7B
3.69% -38.80%
-1.9K
7.81
9.79% -558.28%
28.5B
3.9B
19.96% -3.97%
34.68
7.36
7.75% 11.02%
11.6B
1.1B
13.92% -27.18%
42.59
10.48
13.51% 65.31%
10.1B
801.3M
8.47% -30.79%
63.34
12.97
35.20% 39.92%
MID-CAP
SMALL-CAP
2.0B
137.0M
31.93% -50.56%
-9.53
14.05
12.61% -709.53%
1.1B
159.7M
14.14% -65.84%
-4.68
6.81
19.67% -35.56%
661.5M
23.3M
-6.28% -43.67%
-6.25
28.36
76.56% -106.44%
488.2M
135.3M
-22.87% -81.30%
-3.51
3.42
-2.59% -32.75%
413.2M
110.0M
30.54% -66.08%
-5.25
3.72
3.37% -106.72%
372.0M
132.7M
-1.39% -83.46%
-19.64
2.76
31.03% -107.73%
109.5M
118.0M
6.72% -56.67%
-29.97
0.91
0.97% -269.58%
105.9M
68.8M
4.79% -62.04%
-3.75
1.53
5.65% 26.86%
95.7M
51.6M
-0.71% -16.37%
238.75
1.86
20.72% 150.31%

Financials for Repligen

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue2.9%801779734671593
  S&GA Expenses2.5%215209199184168
  R&D Expenses2.6%4241393432
Earnings Before Taxes3.2%201195179154133
Net Income4.3%166159146128119
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets0.7%2,4632,4452,3842,3582,241
  Current Assets-2.3%953976945932911
    Cash Equivalents-3.9%573597585604621
  Inventory1.5%243239214184156
  Net PPE3.5%174168148125100
  Goodwill-0.3%851854859860834
Liabilities-1.9%627640617608526
  Current Liabilities-3.0%411424424375349
Shareholder's Equity1.6%1,8351,8051,7661,7501,715
  Retained Earnings13.1%34930825817165
  Additional Paid-In Capital0.3%1,5341,529391,560-
Accumulated Depreciation5.9%8479757165
Shares Outstanding0.1%5655555555
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations13.4%16014113311984
  Share Based Compensation-2.1%2829292825
Cashflow From Investing30.2%-174.20-249.40-240.39-221.17-317.18
Cashflow From Financing9.7%-12.83-14.20-11.571300

Risks

What is the probability of a big loss on RGEN?

67.7%


Probability that Repligen stock will be more than 20% underwater in next one year

30.4%


Probability that Repligen stock will be more than 30% underwater in next one year.

18.1%


Probability that Repligen stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does RGEN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Repligen was unfortunately bought at previous high price.

Returns

Cumulative Returns on RGEN

40.7%


10-Year Cumulative Returns

30.7%


7-Year Cumulative Returns

39.3%


5-Year Cumulative Returns

28.4%


3-Year Cumulative Returns

What are the long-term rolling returns for RGEN?

FIve years rolling returns for Repligen.

Which funds bought or sold RGEN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-29
Bridgefront Capital, LLC
-
-
-366,000
-
-%
2022-11-23
Toroso Investments, LLC
NEW
-
202,000
202,000
0.01%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
1,398,000
1,398,000
0.02%
2022-11-22
IHT Wealth Management, LLC
NEW
-
288,000
288,000
0.02%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
40.07
193,000
508,000
0.01%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
1,447,000
12,594,000
0.02%
2022-11-18
D L CARLSON INVESTMENT GROUP INC
REDUCED
-20.79
-174,000
1,828,000
0.40%
2022-11-18
SevenOneSeven Capital Management
-
-
-259,000
-
-%
2022-11-17
M&T Bank Corp
-
-
144,000
1,067,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
ADDED
60.2
330,000
721,000
-%

1–10 of 40

Latest Funds Activity

Are funds buying RGEN calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own RGEN

Repligen News

Seeking Alpha

BBH: Portfolio Of Large-Cap Biotechnology Stocks Has Delivered Strong Returns.37 hours ago

GuruFocus.com

RGEN Fair Value

Recent SEC filings of Repligen

View All Filings
Date Filed Form Type Document
Nov 14, 2022
4
Insider Trading
Nov 01, 2022
8-K
Current Report
Nov 01, 2022
10-Q
Quarterly Report
Oct 11, 2022
4
Insider Trading
Sep 09, 2022
4
Insider Trading
Sep 09, 2022
4
Insider Trading
Sep 08, 2022
SC 13G
Major Ownership Report

Latest Insider Trading transactions for RGEN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-11
Hunt Anthony
ACQUIRED
846,750
33.87
25,000
Chief Executive Officer
2022-11-11
Hunt Anthony
SOLD
-5,000,000
200
-25,000
Chief Executive Officer
2022-10-07
Snodgres Jon
ACQUIRED
27,736.3
59.52
466
Chief Financial Officer
2022-09-09
DAWES KAREN A
SOLD
-176,057
227.17
-775
-
2022-09-08
Hunt Anthony
ACQUIRED
338,700
33.87
10,000
Chief Executive Officer
2022-09-08
Hunt Anthony
SOLD
-5,933,440
224.734
-26,402
Chief Executive Officer
2022-08-16
Snodgres Jon
SOLD
-1,693,690
252.865
-6,698
Chief Financial Officer
2022-08-16
Snodgres Jon
ACQUIRED
471,459
117.366
4,017
Chief Financial Officer
2022-08-11
KURIYEL RALF
SOLD
-1,230,890
254.315
-4,840
Senior VP, R&D
2022-08-11
KURIYEL RALF
ACQUIRED
202,311
50.5777
4,000
Senior VP, R&D

1–10 of 50

Tony J. Hunt
1850
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

RGEN Income Statement

2022-09-30
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:    
Revenue$ 200,741$ 178,216$ 614,774$ 484,013
Costs and operating expenses:    
Cost of product revenue86,51475,495255,130197,232
Research and development10,2289,15432,82325,155
Selling, general and administrative53,64348,373162,592131,809
Contingent consideration(2,309)0(11,604)0
Total costs and operating expenses148,076133,022438,941354,196
Income from operations52,66545,194175,833129,817
Other income (expenses):    
Investment income2,177442,962137
Interest expense(329)(2,859)(892)(8,400)
Amortization of debt issuance costs(455)(361)(1,360)(1,070)
Other expenses(6,591)(786)(10,389)(1,789)
Other expenses, net(5,198)(3,962)(9,679)(11,122)
Income before income taxes47,46741,232166,154118,695
Income tax provision7,0627,73428,92419,514
Net income$ 40,405$ 33,498$ 137,230$ 99,181
Earnings per share:    
Basic$ 0.73$ 0.61$ 2.48$ 1.81
Diluted (Note 12)$ 0.71$ 0.58$ 2.39$ 1.74
Weighted average common shares outstanding:    
Basic55,49855,01555,43254,918
Diluted (Note 12)57,30457,36857,59857,072
Net income$ 40,405$ 33,498$ 137,230$ 99,181
Other comprehensive income (loss):    
Foreign currency translation adjustment(18,170)(5,550)(38,375)(12,004)
Comprehensive income22,23527,94898,85587,177
Products    
Revenue:    
Revenue200,708178,177614,668483,834
Royalty and other revenue    
Revenue:    
Revenue$ 33$ 39$ 106$ 179

RGEN Balance Sheet

2022-09-30
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 573,363$ 603,814
Accounts receivable, net of reserves of $1,350 and $1,417 at September 30, 2022 and December 31, 2021, respectively117,645117,420
Inventories, net242,695184,494
Prepaid expenses and other current assets19,53025,949
Total current assets953,233931,677
Property, plant and equipment, net174,255124,964
Intangible assets, net359,560337,274
Goodwill851,406860,362
Deferred tax assets1,7561,903
Operating lease right of use assets121,522101,559
Other noncurrent assets800615
Total noncurrent assets1,509,2991,426,677
Total assets2,462,5322,358,354
Current liabilities:  
Accounts payable25,25136,203
Operating lease liability13,1568,303
Current contingent consideration13,4910
Accrued liabilities74,63375,498
Convertible Senior Notes, net284,165255,258
Total current liabilities410,696375,262
Deferred tax liabilities23,41333,480
Noncurrent operating lease liability121,190102,492
Noncurrent contingent consideration69,14394,238
Other noncurrent liabilities2,9812,815
Total noncurrent liabilities216,727233,025
Total liabilities627,423608,287
Commitments and contingencies (Note 9)
Stockholders' equity:  
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding00
Common stock, $0.01 par value; 80,000,000 shares authorized; 55,519,646 shares at September 30, 2022 and 55,321,457 shares at December 31, 2021555553
Additional paid-in capital1,541,2721,572,340
Accumulated other comprehensive loss(55,261)(16,886)
Accumulated earnings348,543194,060
Total stockholders' equity1,835,1091,750,067
Total liabilities and stockholders' equity$ 2,462,532$ 2,358,354